SG11201908672WA - Compositions and methods for treating synucleinopathies - Google Patents
Compositions and methods for treating synucleinopathiesInfo
- Publication number
- SG11201908672WA SG11201908672WA SG11201908672WA SG11201908672WA SG 11201908672W A SG11201908672W A SG 11201908672WA SG 11201908672W A SG11201908672W A SG 11201908672WA SG 11201908672W A SG11201908672W A SG 11201908672WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- pct
- applicant
- disease
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 2
- 201000002832 Lewy body dementia Diseases 0.000 abstract 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 2
- 208000009144 Pure autonomic failure Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 231100000673 dose–response relationship Toxicity 0.000 abstract 1
- 210000004558 lewy body Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479818P | 2017-03-31 | 2017-03-31 | |
| US201762528790P | 2017-07-05 | 2017-07-05 | |
| PCT/IB2018/052236 WO2018178950A1 (en) | 2017-03-31 | 2018-03-30 | Compositions and methods for treating synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908672WA true SG11201908672WA (en) | 2019-10-30 |
Family
ID=62092178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908672W SG11201908672WA (en) | 2017-03-31 | 2018-03-30 | Compositions and methods for treating synucleinopathies |
Country Status (13)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5810413B2 (ja) | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗アルファシヌクレイン自己抗体 |
| SG11201906947SA (en) | 2017-02-17 | 2019-08-27 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof |
| WO2019064053A1 (en) * | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| USRE50563E1 (en) | 2017-10-31 | 2025-09-02 | Creative Bio-Peptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| EP3867270A1 (en) * | 2018-10-19 | 2021-08-25 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| CN115151562A (zh) * | 2019-12-04 | 2022-10-04 | Ac免疫有限公司 | 用于治疗和诊断的新分子 |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| IL301039A (en) | 2020-09-10 | 2023-05-01 | Prothena Biosciences Ltd | Treatment of parkinson's disease |
| WO2023041524A2 (en) | 2021-09-16 | 2023-03-23 | H. Lundbeck A/S | Compositions and methods for treating synucleinopathies |
| WO2024167821A2 (en) * | 2023-02-06 | 2024-08-15 | Creative Bio-Peptides, Inc. | Peptides for treating neurological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JP5810413B2 (ja) * | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗アルファシヌクレイン自己抗体 |
| KR101976887B1 (ko) * | 2011-06-23 | 2019-05-09 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | 항-알파 시누클레인 결합 분자 |
| UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
-
2017
- 2017-06-16 JO JOP/2019/0227A patent/JOP20190227A1/ar unknown
-
2018
- 2018-03-30 BR BR112019020335A patent/BR112019020335A2/pt not_active IP Right Cessation
- 2018-03-30 SG SG11201908672W patent/SG11201908672WA/en unknown
- 2018-03-30 US US16/497,055 patent/US20200377579A1/en not_active Abandoned
- 2018-03-30 CN CN201880026858.1A patent/CN110997715A/zh active Pending
- 2018-03-30 MA MA048730A patent/MA48730A/fr unknown
- 2018-03-30 EP EP18721459.8A patent/EP3630815A1/en not_active Withdrawn
- 2018-03-30 AU AU2018242626A patent/AU2018242626A1/en not_active Abandoned
- 2018-03-30 JP JP2019553442A patent/JP2020512368A/ja not_active Withdrawn
- 2018-03-30 KR KR1020197030675A patent/KR20200026789A/ko not_active Abandoned
- 2018-03-30 WO PCT/IB2018/052236 patent/WO2018178950A1/en active Application Filing
- 2018-03-30 CA CA3058304A patent/CA3058304A1/en active Pending
-
2019
- 2019-09-25 IL IL26963719A patent/IL269637A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL269637A (en) | 2019-11-28 |
| CA3058304A1 (en) | 2018-10-04 |
| EP3630815A1 (en) | 2020-04-08 |
| MA48730A (fr) | 2020-04-08 |
| JP2020512368A (ja) | 2020-04-23 |
| BR112019020335A2 (pt) | 2020-04-28 |
| KR20200026789A (ko) | 2020-03-11 |
| WO2018178950A1 (en) | 2018-10-04 |
| CN110997715A (zh) | 2020-04-10 |
| US20200377579A1 (en) | 2020-12-03 |
| JOP20190227A1 (ar) | 2019-09-30 |
| AU2018242626A1 (en) | 2019-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908672WA (en) | Compositions and methods for treating synucleinopathies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201908393YA (en) | Modulators of pcsk9 expression | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201804587QA (en) | Isoindole compounds |